Shared tumor-associated antigen–HLA peptide complexes (Shared TAA-HLA complexes)

Shared tumor-associated antigen–HLA peptide complexes are molecular assemblies presented on the surface of malignant cells, comprising a peptide fragment derived from an intracellular tumor-associated antigen (TAA) bound to a Human Leukocyte Antigen (HLA) molecule. These complexes serve as critical recognition elements for the adaptive immune system, specifically for CD8+ T cells via their T-cell receptors (TCRs) (Source: Nature Reviews Cancer, 2021). Unlike neoantigens derived from unique somatic mutations, shared TAAs—such as NY-ESO-1, MAGE-A4, or PRAME—are expressed across multiple patients and different histological tumor types, allowing for the development of standardized cellular and bispecific therapies (Source: Clinical Cancer Research, 2019). Therapeutic interventions targeting these complexes include TCR-engineered T-cell (TCR-T) therapies and bispecific TCR-like molecules, which bypass natural immune tolerance to specifically lyse cells presenting the target peptide-HLA complex. Clinical efficacy is strictly dependent on both the patient's specific HLA genotype (most commonly HLA-A*02:01) and the tumor's expression of the parent protein (Source: FDA, Tecelra Approval, 2024). A significant challenge in targeting these complexes is the potential for on-target, off-tumor toxicity if the TAA is expressed at low levels in vital healthy tissues, as well as tumor escape through the downregulation of HLA expression (Source: Journal of Clinical Oncology, 2020).

Other names

Shared TAA-peptide-MHC complexesPublic tumor-associated antigensCancer-testis antigen-HLA complexesShared peptide-MHC class I complexesTumor-specific peptide-HLA complexes

Therapeutic agents such as TCR-engineered T-cells (TCR-T) or bispecific T-cell engagers (ImmTACs) utilize a T-cell receptor (TCR) or TCR-mimetic domain to specifically bind the peptide-HLA assembly on the tumor surface. This binding event facilitates the formation of an immunological synapse, leading to T-cell activation and the subsequent release of cytotoxic granules (perforin and granzymes) that induce apoptosis in the target cancer cell (Source: Kim et al., NEJM, 2021; D'Angelo et al., Cancer Discovery, 2018).